Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2012

Open Access 01-12-2012 | Research

PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer

Authors: Dan Su, Haiyan Xu, Jianguo Feng, Yun Gao, Linhui Gu, Lisha Ying, Dionyssios Katsaros, Herbert Yu, Shenhua Xu, Ming Qi

Published in: Journal of Translational Medicine | Issue 1/2012

Login to get access

Abstract

Background

Programmed cell death 6 (PDCD6) beside its known proapoptotic functions may be a player in survival pathways in cancer. The purpose of this study is to further explore the roles of PDCD6 in epithelial ovarian cancer.

Methods

Lentiviral vector with shRNA for PDCD6 was used to investigate the effects of PDCD6 knockdown on cell growth, cell cycle, apoptosis and motility in ovarian cancer cells. Two hundred twelve epithelial ovarian cancer tissues were analyzed for mRNA expression of PDCD6 using RT-PCR. Associations of its expression with clinical pathological factors, progression free and overall survival were evaluated.

Results

PDCD6 is highly expressed in metastatic ovarian cancer cells and positively regulates cell migration and invasion. Significantly, the level of PDCD6 expression in epithelial ovarian cancer correlates with clinical progression. Patients with medium or high levels of PDCD6 mRNA were at higher risk for disease progression, compared to those with low levels (HR, 1.29; P = 0.024 for medium levels; and HR, 1.57; P = 0.045 for high levels) after adjusting for age, disease stage, tumor grade, histologic type and residual tumor size. Kaplan-Meier survival analysis demonstrated similar results. However, no association was found between PDCD6 expression and overall survival.

Conclusions

PDCD6 seems to play an important role in ovarian cancer progression and it may be an independent predictor of progression free survival in epithelial ovarian cancer. Further studies are needed to more completely elucidate the molecular mechanisms of PDCD6 involve in ovarian cancer progression.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer Statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.CrossRefPubMed
2.
du Bois A, Luck HJ, Meier W, Mobus V, Costa S, Richter B, Bauknecht T, Warm M, Schroeder W, Olbricht S: Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynakologische Onkologie. Semin Oncol. 1997, 24: 28-S11.
3.
Aravantinos G, Fountzilas G, Kosmidis P, Dimopoulos MA, Stathopoulos GP, Pavlidis N, Bafaloukos D, Papadimitriou C, Karpathios S, Georgoulias V: Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol. 2005, 16: 1116-1122. 10.1093/annonc/mdi223.CrossRefPubMed
4.
Shenhua X, Hanzhou M, Lijuan Q, Yongzhen S, Chihong Z, Xiaoshu H, Yongliang G, Shanzing D: Establishment and Characterization of a Model of Highly Metastasizing Human Ovarian Cancer Transplanted into Subcutis of the Nude Mice. J Exp Clin Cancer Res. 1995, 14: 387-394.
5.
Shenhua X, Lijuan Q, Hanzhou N, Xinghao N, Chihong Z, Gu Z, Weifang D, Yongliang G: Establishment of a highly metastatic human ovarian cancer cell line (HO-8910 PM) and its characterization. J Exp Clin Cancer Res. 1999, 18: 233-239.PubMed
6.
Su D, Xu SH, Gu LH: Comparative proteomics analysis of differentially expressed metastasis-associated proteins in human ovarian cancer cell lines. Zhonghua Fu Chan Ke Za Zhi. 2005, 40: 619-622.PubMed
7.
Jung YS, Kim KS, Dong Kim K, Lim JS, Kim JW, Kim E: Apoptosis-Linked Gene 2 Binds to the Death Domain of Fas and Dissociates from Fas during Fas-Mediated Apoptosis in Jurkat Cells. Biochem Biophys Res Commun. 2001, 288: 420-426. 10.1006/bbrc.2001.5769.CrossRefPubMed
8.
Shibata H, Yamada K, Mizuno T, Yorikawa C, Takahashi H, Satoh H, Kitaura Y, Maki M: The Penta-EF-Hand Protein ALG-2 Interacts with a Region Containing PxY Repeats in Alix/AIP1, Which Is Required for the Subcellular Punctate Distribution of the Amino-Terminal Truncation Form of Alix/AIP1. J Biochem. 2004, 135: 117-10.1093/jb/mvh014.CrossRefPubMed
9.
Jang IK, Hu R, Lacana E, D'Adamio L, Gu H: Apoptosis-Linked Gene 2-Deficient Mice Exhibit Normal T-Cell Development and Function. Mol Cell Biol. 2002, 22: 4094-4100. 10.1128/MCB.22.12.4094-4100.2002.CrossRefPubMedPubMedCentral
10.
la Cour JM, Mollerup J, Winding P, Tarabykina S, Sehested M, Berchtold MW: Up-Regulation of ALG-2 in Hepatomas and Lung Cancer Tissue. Am J Pathol. 2003, 163: 81-89. 10.1016/S0002-9440(10)63632-2.CrossRefPubMedPubMedCentral
11.
Shepherd JH: Revised FIGO staging for gynaecological cancer. BJOG: An Int J Obstetrics Gynaecology. 1989, 96: 889-892. 10.1111/j.1471-0528.1989.tb03341.x.CrossRef
12.
Scully RE, Sobin LH: Histologic typing of ovarian tumors. Arch Pathol Lab Med. 1987, 111: 794-795.PubMed
13.
Vito P, Lacana E, D'Adamio L: Interfering with apoptosis: Ca(2+)-binding protein ALG-2 and Alzheimer's disease gene ALG-3. Science. 1996, 271: 521-525. 10.1126/science.271.5248.521.CrossRefPubMed
14.
Maki M, Narayana SV, Hitomi K: A growing family of the Ca2 + -binding proteins with five EF-hand motifs. Biochem J. 1997, 328 (Pt 2): 718-720.PubMedPubMedCentral
15.
Maki M, Yamaguchi K, Kitaura Y, Satoh H, Hitomi K: Calcium-induced exposure of a hydrophobic surface of mouse ALG-2, which is a member of the penta-EF-hand protein family. J Biochem. 1998, 124: 1170-1177.CrossRefPubMed
16.
Suzuki H, Kawasaki M, Inuzuka T, Okumura M, Kakiuchi T, Shibata H, Wakatsuki S, Maki M: The mechanism of Ca2 + -dependent recognition of Alix by ALG-2: insights from X-ray crystal structures. Biochem Soc Trans. 2009, 37: 190-194. 10.1042/BST0370190.CrossRefPubMed
17.
Satoh H, Nakano Y, Shibata H, Maki M: The penta-EF-hand domain of ALG-2 interacts with amino-terminal domains of both annexin VII and annexin XI in a Ca2 + -dependent manner. Biochim Biophys Acta. 2002, 1600: 61-67.CrossRefPubMed
18.
Shibata H, Suzuki H, Yoshida H, Maki M: ALG-2 directly binds Sec31A and localizes at endoplasmic reticulum exit sites in a Ca2 + -dependent manner. Biochem Biophys Res Commun. 2007, 353: 756-763. 10.1016/j.bbrc.2006.12.101.CrossRefPubMed
19.
D'Adamio L, Lacana E, Vito P: Functional cloning of genes involved in T-cell receptor-induced programmed cell death. Semin Immunol. 1997, 9: 17-23. 10.1006/smim.1996.0057.CrossRefPubMed
20.
Mahul-Mellier AL, Strappazzon F, Petiot A, Chatellard-Causse C, Torch S, Blot B, Freeman K, Kuhn L, Garin J, Verna JM: Alix and ALG-2 Are Involved in Tumor Necrosis Factor Receptor 1-induced Cell Death. J Biol Chem. 2008, 283: 34954-10.1074/jbc.M803140200.CrossRefPubMedPubMedCentral
21.
Jang IK, Hu R, Lacana E, D'Adamio L, Gu H: Apoptosis-linked gene 2-deficient mice exhibit normal T-cell development and function. Mol Cell Biol. 2002, 22: 4094-4100. 10.1128/MCB.22.12.4094-4100.2002.CrossRefPubMedPubMedCentral
22.
la Cour JM, Mollerup J, Winding P, Tarabykina S, Sehested M, Berchtold MW: Up-regulation of ALG-2 in hepatomas and lung cancer tissue. Am J Pathol. 2003, 163: 81-89. 10.1016/S0002-9440(10)63632-2.CrossRefPubMedPubMedCentral
23.
Aviel-Ronen S, Coe BP, Lau SK: da Cunha Santos G, Zhu CQ, Strumpf D, Jurisica I, Lam WL, Tsao MS: Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. Proc Natl Acad Sci USA. 2008, 105: 10155-10160. 10.1073/pnas.0709618105.CrossRefPubMedPubMedCentral
24.
la Cour JM, Hj BR, Mollerup J, Simon R, Sauter G, Berchtold MW: The apoptosis linked gene ALG-2 is dysregulated in tumors of various origin and contributes to cancer cell viability. Molecular Oncology. 2008, 1: 431-439. 10.1016/j.molonc.2007.08.002.CrossRefPubMed
25.
Hoj BR, la Cour JM, Mollerup J, Berchtold MW: ALG-2 knockdown in HeLa cells results in G2/M cell cycle phase accumulation and cell death. Biochem Biophys Res Commun. 2009, 378: 145-148. 10.1016/j.bbrc.2008.11.021.CrossRefPubMed
26.
la Cour JM, Hoj BR, Mollerup J, Simon R, Sauter G, Berchtold MW: The apoptosis linked gene ALG-2 is dysregulated in tumors of various origin and contributes to cancer cell viability. Mol Oncol. 2008, 1: 431-439. 10.1016/j.molonc.2007.08.002.CrossRefPubMed
27.
Rho SB, Song YJ, Lim MC, Lee SH, Kim BR, Park SY: Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. Cell Signal. 2012, 24: 131-139. 10.1016/j.cellsig.2011.08.013.CrossRefPubMed
Metadata
Title
PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer
Authors
Dan Su
Haiyan Xu
Jianguo Feng
Yun Gao
Linhui Gu
Lisha Ying
Dionyssios Katsaros
Herbert Yu
Shenhua Xu
Ming Qi
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2012
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-10-31

Other articles of this Issue 1/2012

Journal of Translational Medicine 1/2012 Go to the issue

Research

Matrix Metalloproteinase-dependent turnover of cartilage, synovial membrane, and connective tissue is elevated in rats with collagen induced arthritis

Research

Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis

Research

Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury

Methodology

Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells

Research

The globular heads of the C1q receptor regulate apoptosis in human cervical squamous carcinoma cells via a p53-dependent pathway

Research

Parvovirus B19V DNA contamination in Chinese plasma and plasma derivatives
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits